Literature DB >> 9108189

Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

F Montella1, P Pezzotti, F Di Sora, O Recchia, F Lauria, G Rezza.   

Abstract

A population of 549 HIV-positive intravenous drug users, 140 of whom were women, recruited between June 1985 and June 1991, were studied to determine the usefulness of minor clinical signs and biological parameters in predicting progression to AIDS at different CD4+ levels. Ninety-eight subjects developed AIDS during a median follow-up of 4 years. Oral thrush was predictive of progression to AIDS independently of the CD4+ level at enrollment; seborrheic dermatitis was predictive of disease progression only in those with CD4+ under 500 cells/mm3. Regarding the predictive value of the biologic parameters examined, similar IgA levels among HIV-seropositive intravenous drug users with CD4+ > 500 cells/mm3 and HIV-negative intravenous drug users were observed, while higher median levels were found among HIV-positive participants with CD4+ level under 500 cells/mm3. Among intravenous drug users with CD4+ < 500 cells/mm3, a level of IgA higher than 200 mg/dl at enrollment was predictive of faster progression to AIDS. Among participants with CD4+ [corrected] over 500 cells/mm3, an IgA level above 400 mg/dl was still predictive of faster progression, but the sensitivity tended to be low. These findings suggest that an elevated level of IgA and presence of oral thrush may be important early markers of disease progression in HIV-infected intravenous drug users. Seborrheic dermatitis is also predictive, but only in later stages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108189     DOI: 10.1007/bf02113591

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals.

Authors:  A B Mariotto; S Mariotti; P Pezzotti; G Rezza; A Verdecchia
Journal:  Am J Epidemiol       Date:  1992-02-15       Impact factor: 4.897

2.  Prognostic indicators for development of AIDS among intravenous drug users.

Authors:  A Muñoz; D Vlahov; L Solomon; J B Margolick; J C Bareta; S Cohn; J Astemborski; K E Nelson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

3.  Risk of AIDS in HIV seroconverters: a comparison between intravenous drug users and homosexual males.

Authors:  G Rezza; A Lazzarin; G Angarano; R Zerboni; A Sinicco; B Salassa; R Pristerà; M Barbanera; L Ortona; F Aiuti
Journal:  Eur J Epidemiol       Date:  1990-03       Impact factor: 8.082

4.  Markers for disease progression in intravenous drug users infected with HIV-1.

Authors:  R Zangerle; D Fuchs; G Reibnegger; P Fritsch; H Wachter
Journal:  AIDS       Date:  1991-08       Impact factor: 4.177

5.  Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study.

Authors: 
Journal:  AIDS       Date:  1992-04       Impact factor: 4.177

6.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; P Alcabes; D Hartel; D Buono; E E Schoenbaum; R S Klein; K Davenny; G H Friedland
Journal:  N Engl J Med       Date:  1992-12-10       Impact factor: 91.245

7.  Beta 2-microglobulin levels in drug users: the influence of risk behaviour.

Authors:  P J Flegg; R P Brettle; J R Robertson; R C Clarkson; A G Bird
Journal:  AIDS       Date:  1991-08       Impact factor: 4.177

8.  Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.

Authors: 
Journal:  AIDS       Date:  1994-07       Impact factor: 4.177

9.  Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users.

Authors:  E Fernández-Cruz; M Desco; M Garcia Montes; N Longo; B Gonzalez; J M Zabay
Journal:  AIDS       Date:  1990-10       Impact factor: 4.177

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  3 in total

1.  Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis.

Authors:  V L da Matta; S Hoshino-Shimizu; R Dietze; C E Corbett
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 2.  Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review.

Authors:  Michael-John S Milloy; Brandon D L Marshall; Thomas Kerr; Jane Buxton; Tim Rhodes; Julio Montaner; Evan Wood
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

Review 3.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.